Loading
A bispecific ADC is an ADC whose antibody grabs two different proteins on the cancer cell, so it sticks better to tumour and less to healthy tissue.
Izalontamab brengitecan (iza-bren, EGFR×HER3, SystImmune/BMS) is the first bispecific ADC with positive phase 3 results, meeting PFS and OS in previously treated TNBC (BL-B01D1-307, February 2026) and in oesophageal cancer, with first-line trials (IZABRIGHT-Breast01) ongoing. Eight bsADC phase 3 trials started in 2025. c-MET×EGFR is the most crowded pair (tilatamig samrotecan, AZD9592, 24 candidates); Nectin-4×TROP2 (AK146D1, AVZO-103), HER2 biparatopic (zanidatamab zovodotin), and PD-L1×B7-H3 (BH4601) follow.
Dual antigen binding increases avidity and internalisation and can enable lysosomal trafficking (e.g., pairing with a rapidly internalising receptor). Biparatopic designs cross-link one receptor.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
AK146D1 is Akeso's Nectin-4 × TROP2 bispecific ADC, combining the two most validated ADC addresses in one molecule.
AVZO-103 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.
BCG033 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.
IBI3014 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.
Izalontamab brengitecan is the first bispecific ADC to succeed in a phase 3 trial, hitting two growth receptors at once in triple-negative breast cancer.
JSKN016 is an experimental drug that targets two proteins on cancer cells and carries chemotherapy. It has reached phase 3 testing; earlier response findings do not prove comparative benefit.
AstraZeneca's EGFR×c-MET bispecific ADC, the most advanced in the most crowded next-generation ADC target pair.
VBC103 is an experimental drug designed to recognize two proteins on cancer cells. Its early trial is testing safety and activity.
Query for this technology: (TITLE:"bispecific antibody-drug conjugate" OR ABSTRACT:"bispecific antibody-drug conjugate" OR TITLE:"bispecific ADC" OR ABSTRACT:"bispecific ADC"). Results are unfiltered search hits about Bispecific ADC, not a curated reading list.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, TROP2, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag frontier.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Acquired resistance to every therapy, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Logic-gated therapeutics (AND, NOT gates), ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Nectin-4, B7-H3, Bladder & urothelial cancer and the tag frontier.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, HER2, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Logic-gated therapeutics (AND, NOT gates), Bristol Myers Squibb and the tag frontier.
Shares Acquired resistance to every therapy, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/